tetano
Editor, Senior Moderator
Pharmaceuticals (Basel)
. 2021 Jan 8;14(1):E44.
doi: 10.3390/ph14010044.
Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
Praveen P N Rao[SUP] 1 [/SUP], Amy Trinh Pham[SUP] 1 [/SUP], Arash Shakeri[SUP] 1 [/SUP], Amna El Shatshat[SUP] 1 [/SUP], Yusheng Zhao[SUP] 1 [/SUP], Rahul C Karuturi[SUP] 1 [/SUP], Ahmed A Hefny[SUP] 1 [/SUP]
Affiliations
Abstract
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally. As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-2 infections due to their advantages such as superior patient compliance for oral therapies, reduced manufacturing costs and ease of large scale distribution due to better stability and storage profiles. Discovering new drugs for SARS-CoV-2 infections is a time consuming and expensive proposition. In this regard, drug repurposing is an appealing approach which can provide rapid access to therapeutics with proven record of safety and efficacy. We investigated the drug repurposing potential of a library of dipeptidyl peptidase 4 (DPP4) inhibitors which are currently marketed for type-2 diabetes as treatment option for SARS-CoV-2 infections. These computational studies led to the identification of three marketed DPP4 inhibitors; gemigliptin, linagliptin and evogliptin as potential inhibitors of SARS-CoV-2 M[SUP]pro[/SUP] viral cysteine protease. In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV M[SUP]pro[/SUP] and MERS-CoV CL[SUP]pro[/SUP] suggesting their potential to be repurposed as broad-spectrum antiviral agents.
Keywords: MERS-CoV CLpro; SARS-CoV-2 Mpro dimer; SARS-CoV-2 Mpro protomer; SARS-CoV-2 infection; cysteine proteases; dipeptidyl peptidase IV inhibitors; drug repurposing; molecular docking; serine proteases; type-2 diabetes.
. 2021 Jan 8;14(1):E44.
doi: 10.3390/ph14010044.
Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
Praveen P N Rao[SUP] 1 [/SUP], Amy Trinh Pham[SUP] 1 [/SUP], Arash Shakeri[SUP] 1 [/SUP], Amna El Shatshat[SUP] 1 [/SUP], Yusheng Zhao[SUP] 1 [/SUP], Rahul C Karuturi[SUP] 1 [/SUP], Ahmed A Hefny[SUP] 1 [/SUP]
Affiliations
- PMID: 33430081
- DOI: 10.3390/ph14010044
Abstract
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally. As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-2 infections due to their advantages such as superior patient compliance for oral therapies, reduced manufacturing costs and ease of large scale distribution due to better stability and storage profiles. Discovering new drugs for SARS-CoV-2 infections is a time consuming and expensive proposition. In this regard, drug repurposing is an appealing approach which can provide rapid access to therapeutics with proven record of safety and efficacy. We investigated the drug repurposing potential of a library of dipeptidyl peptidase 4 (DPP4) inhibitors which are currently marketed for type-2 diabetes as treatment option for SARS-CoV-2 infections. These computational studies led to the identification of three marketed DPP4 inhibitors; gemigliptin, linagliptin and evogliptin as potential inhibitors of SARS-CoV-2 M[SUP]pro[/SUP] viral cysteine protease. In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV M[SUP]pro[/SUP] and MERS-CoV CL[SUP]pro[/SUP] suggesting their potential to be repurposed as broad-spectrum antiviral agents.
Keywords: MERS-CoV CLpro; SARS-CoV-2 Mpro dimer; SARS-CoV-2 Mpro protomer; SARS-CoV-2 infection; cysteine proteases; dipeptidyl peptidase IV inhibitors; drug repurposing; molecular docking; serine proteases; type-2 diabetes.